H Bryan Brewer

Summary

Country: USA

Publications

  1. ncbi request reprint Focus on high-density lipoproteins in reducing cardiovascular risk
    H Bryan Brewer
    Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Am Heart J 148:S14-8. 2004
  2. ncbi request reprint Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Scott M Grundy
    Circulation 110:227-39. 2004
  3. ncbi request reprint Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease
    H Bryan Brewer
    Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Arterioscler Thromb Vasc Biol 24:1755-60. 2004
  4. ncbi request reprint HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease
    H Bryan Brewer
    Department of Lipoprotein and Atherosclerosis Research, Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, Washington, DC 20010, USA
    Curr Cardiol Rep 9:486-92. 2007
  5. doi request reprint Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease
    H Bryan Brewer
    Cardiovascular Research Institute, MedStar Health, 110 Irving Street, Suite 4B 1, Washington, DC 20010, USA
    J Clin Endocrinol Metab 96:1246-57. 2011
  6. doi request reprint A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome
    Ron Waksman
    Department of Internal Medicine, Division of Cardiology, Washington Hospital Center, Washington, DC 20010, USA
    J Am Coll Cardiol 55:2727-35. 2010
  7. pmc Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo
    Frank M Sacks
    Harvard School of Public Health and Harvard Medical School, Boston, MA, USA, USA
    J Lipid Res 50:894-907. 2009
  8. ncbi request reprint The orphan nuclear receptor LRH-1 activates the ABCG5/ABCG8 intergenic promoter
    Lita A Freeman
    Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    J Lipid Res 45:1197-206. 2004
  9. ncbi request reprint Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Scott M Grundy
    Arterioscler Thromb Vasc Biol 24:e149-61. 2004
  10. ncbi request reprint Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
    Scott M Grundy
    J Am Coll Cardiol 44:720-32. 2004

Collaborators

Detail Information

Publications32

  1. ncbi request reprint Focus on high-density lipoproteins in reducing cardiovascular risk
    H Bryan Brewer
    Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Am Heart J 148:S14-8. 2004
    ....
  2. ncbi request reprint Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Scott M Grundy
    Circulation 110:227-39. 2004
    ..Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy...
  3. ncbi request reprint Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease
    H Bryan Brewer
    Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Arterioscler Thromb Vasc Biol 24:1755-60. 2004
    ....
  4. ncbi request reprint HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease
    H Bryan Brewer
    Department of Lipoprotein and Atherosclerosis Research, Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, Washington, DC 20010, USA
    Curr Cardiol Rep 9:486-92. 2007
    ..Definitive clinical trials will now be required to establish the safety and efficacy of increasing HDL in the treatment of patients with cardiovascular disease...
  5. doi request reprint Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease
    H Bryan Brewer
    Cardiovascular Research Institute, MedStar Health, 110 Irving Street, Suite 4B 1, Washington, DC 20010, USA
    J Clin Endocrinol Metab 96:1246-57. 2011
    ..Statin treatment of cardiovascular patients reduces clinical events by 25 to 45%. High-density lipoprotein (HDL) has been proposed as a therapeutic target to further reduce this residual cardiovascular risk...
  6. doi request reprint A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome
    Ron Waksman
    Department of Internal Medicine, Division of Cardiology, Washington Hospital Center, Washington, DC 20010, USA
    J Am Coll Cardiol 55:2727-35. 2010
    ..This study aimed to determine whether serial autologous infusions of selective high-density lipoprotein (HDL) delipidated plasma are feasible and well tolerated in patients with acute coronary syndrome (ACS)...
  7. pmc Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo
    Frank M Sacks
    Harvard School of Public Health and Harvard Medical School, Boston, MA, USA, USA
    J Lipid Res 50:894-907. 2009
    ..Treatment with delipidated plasma tended to reduce diet-induced aortic atherosclerosis in monkeys measured by intravascular ultrasound. These findings link the conversion of small to large HDL, in vivo, to improvement in atherosclerosis...
  8. ncbi request reprint The orphan nuclear receptor LRH-1 activates the ABCG5/ABCG8 intergenic promoter
    Lita A Freeman
    Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    J Lipid Res 45:1197-206. 2004
    ....
  9. ncbi request reprint Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Scott M Grundy
    Arterioscler Thromb Vasc Biol 24:e149-61. 2004
    ..Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy...
  10. ncbi request reprint Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
    Scott M Grundy
    J Am Coll Cardiol 44:720-32. 2004
    ..Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy...
  11. ncbi request reprint Serum amyloid A promotes ABCA1-dependent and ABCA1-independent lipid efflux from cells
    John A Stonik
    National Institutes of Health Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    Biochem Biophys Res Commun 321:936-41. 2004
    ..These results suggest that SAA may play a unique role as an auxiliary lipid acceptor in the removal of lipid from sites of inflammation...
  12. ncbi request reprint The human ABCG1 gene: identification of LXR response elements that modulate expression in macrophages and liver
    Steven L Sabol
    Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Lipid Res 46:2151-67. 2005
    ..These studies clarify the mechanism of transcriptional upregulation of the ABCG1 gene by oxysterols in macrophages and liver, two key tissues where ABCG1 expression may affect cholesterol balance and atherogenesis...
  13. ncbi request reprint Effect of ACAT inhibition on the progression of coronary atherosclerosis
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    N Engl J Med 354:1253-63. 2006
    ..The enzyme acyl-coenzyme A:cholesterol acyltransferase (ACAT) esterifies cholesterol in a variety of tissues. In some animal models, ACAT inhibitors have antiatherosclerotic effects...
  14. ncbi request reprint ABCA1 overexpression in the liver of LDLr-KO mice leads to accumulation of pro-atherogenic lipoproteins and enhanced atherosclerosis
    Charles W Joyce
    Molecular Disease Section, NHLBI, National Institutes of Health, Bethesda, MD 20892, USA
    J Biol Chem 281:33053-65. 2006
    ....
  15. ncbi request reprint Hepatic ABCG5/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited
    Federica Basso
    Molecular Disease Section, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    J Lipid Res 48:114-26. 2007
    ..These findings identify distinct roles for liver and intestinal ABCG5/G8 in modulating sterol metabolism and atherosclerosis...
  16. ncbi request reprint Hepatic ABCG5 and ABCG8 overexpression increases hepatobiliary sterol transport but does not alter aortic atherosclerosis in transgenic mice
    Justina E Wu
    Molecular Disease Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 279:22913-25. 2004
    ..These findings demonstrate that overexpression of ABCG5/G8 in the liver profoundly alters hepatic but not intestinal sterol transport, identifying distinct roles for liver and intestinal ABCG5/G8 in modulating sterol metabolism...
  17. ncbi request reprint High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease
    H Bryan Brewer
    Arterioscler Thromb Vasc Biol 24:387-91. 2004
  18. ncbi request reprint Rising to the challenge of the new NCEP ATP III guidelines: exceeding current therapeutic limitations
    H Bryan Brewer
    Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
    Am J Manag Care 8:S23-8; discussion S45-7. 2002
    ..These mechanisms and others also suggest new targets for therapeutic intervention and the development of new drugs that will correct lipid and lipoprotein abnormalities through a number of different metabolic pathways...
  19. ncbi request reprint The E-box motif in the proximal ABCA1 promoter mediates transcriptional repression of the ABCA1 gene
    Xiao Ping Yang
    Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1666, USA
    J Lipid Res 43:297-306. 2002
    ..These combined studies identify a novel site in the human ABCA1 promoter involved in the regulation of ABCA1 gene expression...
  20. pmc Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux
    Taro E Akiyama
    Laboratory of Metabolism, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Cell Biol 22:2607-19. 2002
    ..Together, these data indicate that PPAR gamma plays a critical role in the regulation of cholesterol homeostasis by controlling the expression of a network of genes that mediate cholesterol efflux from cells and its transport in plasma...
  21. ncbi request reprint The ABCA1 transporter functions on the basolateral surface of hepatocytes
    Edward B Neufeld
    Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 7N115, 10 Center Drive, 20892, Bethesda, MD 20892, USA
    Biochem Biophys Res Commun 297:974-9. 2002
    ..These findings suggest an important role for hepatocyte basolateral membrane ABCA1 in the regulation of the levels of intracellular hepatic cholesterol, as well as plasma HDL...
  22. ncbi request reprint In vivo metabolism of apolipoprotein E within the HDL subpopulations LpE, LpE:A-I, LpE:A-II and LpE:A-I:A-II
    Minna L Hannuksela
    Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Atherosclerosis 165:205-20. 2002
    ..These differences were related to the lipid and apolipoprotein composition of the HDL subspecies, and, in control subjects, to the transfer of apoE from HDL subspecies to apoB-containing lipoproteins as well...
  23. ncbi request reprint Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway
    Alan T Remaley
    National Institutes of Health Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA
    J Lipid Res 44:828-36. 2003
    ..In addition, unlike apoA-I, synthetic peptides can also efflux lipid by a passive, energy-independent pathway that does not involve ABCA1 but does depend upon their lipid affinity...
  24. ncbi request reprint Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations
    Federica Basso
    Molecular Disease Branch, NHLBI, National Institutes of Health, Bethesda, MD 20862, USA
    J Lipid Res 44:296-302. 2003
    ..These combined results demonstrate that ABCA1 plays a key role in hepatic cholesterol efflux, inducing pathways that modulate cholesterol homeostasis in the liver, and establish the liver as a major source of plasma HDL-C...
  25. ncbi request reprint Study of ABCA1 function in transgenic mice
    Charles Joyce
    Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Arterioscler Thromb Vasc Biol 23:965-71. 2003
    ..The present review summarizes the most recent studies and discusses insights provided by these transgenic mouse models...
  26. ncbi request reprint New insights into the role of the adenosine triphosphate-binding cassette transporters in high-density lipoprotein metabolism and reverse cholesterol transport
    H Bryan Brewer
    Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Cardiol 91:3E-11E. 2003
    ..The ABC transporters currently represent excellent targets for the development of new drugs for the treatment of patients with increased risk of premature cardiovascular disease...
  27. ncbi request reprint Low-density lipoprotein receptor and apolipoprotein A-I and B expression in human enterocytes
    Dmitri Sviridov
    Molecular Disease Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Digestion 67:67-70. 2003
    ..Immunoprecipitation of [(35)S]methionine pulse-labeled intracellular proteins from these cell types demonstrated that human enterocytes synthesize more apoA-I and apoB, while HepG2 cells synthesize a slightly higher amount of LDL-R...
  28. ncbi request reprint Clinical significance of high-density lipoproteins and the development of atherosclerosis: focus on the role of the adenosine triphosphate-binding cassette protein A1 transporter
    H Bryan Brewer
    Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20894, USA
    Am J Cardiol 92:10K-16K. 2003
    ..Ongoing investigation of mechanisms by which HDL acts to reduce the risk of atherosclerosis will provide several new targets for the development of drugs to decrease the risk of atherosclerosis...
  29. ncbi request reprint Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams
    H Bryan Brewer
    Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20894, USA
    Am J Cardiol 92:23K-29K. 2003
    ..2% of patients receiving rosuvastatin and those receiving atorvastatin, simvastatin, and pravastatin. Compared with other widely used statins, the benefit-risk profile of rosuvastatin 10 to 40 mg appears to be very favorable...
  30. ncbi request reprint Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition
    Scott M Grundy
    Circulation 109:433-8. 2004
  31. ncbi request reprint The ABCA1 transporter modulates late endocytic trafficking: insights from the correction of the genetic defect in Tangier disease
    Edward B Neufeld
    Molecular Disease Branch, NHLBI, NHLBI Light Microscopy Core Facility, and Laboratory for Cellular Biology and Biochemistry, NIDDK, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 279:15571-8. 2004
    ..The combined results of this study suggest that ABCA1 converts pools of late endocytic lipids that retain NPC1 to pools that can associate with endocytosed apoA-I, and be released from the cell as nascent high density lipoprotein...
  32. pmc The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice
    Charles W Joyce
    Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 99:407-12. 2002
    ....